 Characterization Bay novel thromboxane receptor antagonist thromboxane antagonistic properties Bay o-lepropanoic acid various pharmacologic models Bay inhibits platelet aggregation collagen platelet-activating factor second wave ADP microM human plasma plasma phase ADP-induced aggregation platelet aggregation humans platelet aggregation oral application mg Bay Bay antagonizes contractions rabbit aortic rings vivo Bay rabbits arachidonic acid collagen-induced thromboembolism mg/kg p.o Chronic administration Bay stroke-prone hypertensive rats stroke-related mortality occurrence cerebral hemorrhages results Bay active selective competitive thromboxane antagonist beneficial treatment cardiovascular cerebrovascular diseases